Researchers have for the first time documented a case of an individual contracting HIV, a multi-drug resistant strain, while apparently adhering well to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP). The scientists concluded that it is indeed possible for individuals who are adherent to PrEP to contract HIV when they are exposed to a virus that is resistant to both drugs included in Truvada.
Tap here to turn on desktop notifications to get the news sent straight to you.
Real Life. Real News. Real Voices.
Help us tell more of the stories that matter from voices that too often remain unheard.